ClinicalTrials.gg
RecruitingNCT06788522Updated Nov 5, 2026

The Effects of Orexin Antagonism on Fear Extinction in PTSD

A Phase 4 interventional study of Suvorexant and Placebo in Insomnia and PTSD, sponsored by VA Office of Research and Development. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by VA Office of Research and Development · Phase 4, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 5, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40,120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders — 5 open to participants now, 5 under way, 1 of them phase 3. suvorexant · Sleep Initiation and Maintenance Disorders.

Planned enrollment
Largest of 38
40,120 · median 44
Started
2026
with 1 other
Phase 4
22 of 38
2 open now
Registered
36th of 38
by date
Lead sponsor
2 of 38
VA Office of Research and Development

Among the 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders, this one has the largest planned enrollment, is one of 2 that started in 2026, is one of 22 in phase 4, and was the 36th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

5 of the 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About suvorexant

suvorexant: first FDA approval 2014 (BELSOMRA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

PTSD affects approximately 22% of Veterans who have served in Iraq and Afghanistan. Symptoms of PTSD may include re-experiencing, avoidance of trauma reminders, negative thoughts or feelings, and hyperarousal, such as increased startle reactivity and disturbed sleep. Treatments for PTSD are based on fear extinction principles in which individuals are repeatedly exposed a feared cue in the absence of danger, resulting in diminishing physiological reactions, a process believed to underlie recovery from PTSD. Studies suggest that orexin, a wake-promoting neuropeptide, may enhance fear extinction. This study will examine whether suvorexant, a selective orexin-receptor antagonist, will enhance fear extinction in Veterans with PTSD and insomnia. Finding a role for orexins in fear extinction will support the rationale for its further evaluation in the treatment of PTSD. Suvorexant is an accessible, safe medication that has been well-established in treating insomnia. It has outstanding promise for treating common and distressing symptoms in Veterans with PTSD.

Read the detailed description

PTSD is a common consequence of combat manifested in part by trauma-related arousal and reactivity, seen in increased startle and impaired sleep that result from central and autonomic nervous system alterations. Impaired fear extinction may explain prolonged physiological alterations in PTSD. Preclinical evidence suggests that orexin, a wake-promoting neuropeptide, may be a shared mechanism underlying both sleep and fear extinction. While rodent studies have shown that pharmacological manipulations that block orexin in rodents facilitate fear extinction, no studies have tested this in humans with PTSD.

In line with the CSRD Combined Proof of Concept and Clinical Trial Merit Review Award mechanism, the investigators propose a proof-of-concept study leading to a clinical trial. During the initial phase, the investigators will develop and establish feasibility of the task and recruitment in 40 eligible participants with PTSD and insomnia. The task will involve a home-based multi-day remote fear conditioning experimental study, in which Veterans with PTSD and insomnia will receive nightly doses of suvorexant or placebo following extinction training over the subsequent 6 nights. Primary Aims of the proof of concept will be to: 1) establish remote fear conditioning procedures collaboratively with Veteran stakeholders; 2) evaluate enrollment, tolerability, adherence, and retention; 3) demonstrate fear conditioning and extinction learning using remote procedures; and 4) determine task feasibility of the home-based remote fear conditioning task. Go/No go milestones include: 1) the ability to enroll and randomize 40 participants by the end of month 23; 2) most participants (> 80%) will take medication as prescribed over 7 nights; 3) no SAEs during the course of treatment as determined by the data monitoring committee review (DMC); 4) \< 10% of post-randomization participants will drop out (\<4 participants), resulting in 36 individuals who complete all study procedures by month 23; 5) successful demonstration of measurement of fear conditioning (greater skin conductance (SC) responses to CS+ cues vs CS- cues) and fear extinction (differential SC responses to CS+ and CS- cues that diminish over trials) in the combined sample; 6) feasibility of the remote task demonstrated by \<15% data loss due to recording issues (e.g., technical malfunction or UCS non-response in \<6 participants).

If milestones are met, the investigators will advance to a clinical mechanistic trial to evaluate suvorexant in facilitating fear extinction using a double-blind randomized, placebo-controlled experimental design in Veterans with PTSD and insomnia. A total of 120 male and female Veterans with PTSD and insomnia will be randomized to either the suvorexant or placebo condition (n=60 in each condition). Participants will be trained in multi-day remote procedures involving fear conditioning (Day 1) and extinction 3 days later (Day 4), followed by 10 mg. suvorexant or placebo. A flexible dose titration of suvorexant (10-20 mg.) or matching placebo will be administered over the next 6 nights. Participants will then undergo extinction retention and fear reinstatement tests one week after extinction (Day 11). Primary outcome measures will be differential skin conductance responses to CS+ and CS- cues during extinction retention and reinstatement phases.

Primary Aims of the Clinical Trial will be: 1) To examine whether suvorexant facilitates fear extinction, seen as greater extinction retention compared to placebo. 2) To examine whether the facilitative effects of suvorexant are more resistant to reinstatement compared to placebo. Pending an effect of suvorexant on fear extinction retention and reinstatement, the investigators will evaluate whether improvement in insomnia mediates these effects. In-home sleep recording (including both sleep EEG and indices of sleep-disordered breathing) and sleep diary measures will be examined as secondary mediators. Greater improvement in sleep quality will partially account for greater extinction retention and less reinstatement. If successful, the proposed study will offer proof-of-concept data and meaningful guidance for future studies of suvorexant as an augmentation co-treatment in exposure therapy.

03

Conditions studied

  • Insomnia
  • PTSD

Keywords

  • Fear conditioning
  • PTSD
  • Insomnia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (same for Phase 1 and Phase 2):

    • men and women
    • a history of US military service
    • capable of reading and understanding English
    • able to provide written
  • Criterion A event meets criteria and occurred during military service, including combat and military sexual trauma
  • Chronic full PTSD diagnosis >3 months duration as indexed by CAPS-5 at screening, and CAPS-5 score > 30
  • Insomnia indicated by insomnia severity index (ISI) score > 14
  • Subjects on non-exclusionary medications, and must be on a stable dose for at least 4 weeks prior to randomization, including Selective Serotonin Reuptake Inhibitors (SSRIs, e.g.,):

    • sertraline
    • paroxetine
    • fluoxetine
    • fluvoxamine
    • citalopram
    • escitalopram
  • Serotonin-norepinephrine reuptake inhibitors (SNRIs; e.g.):

    • Desvenlafaxine
    • Duloxetine
    • Levomilnacipran
    • Venlafaxine
  • For subjects who are in psychotherapy, treatment must be stable for 6 weeks
  • Women of must not be pregnant or have plans for pregnancy or breastfeeding during the study and must use a medically acceptable method of

Exclusion criteria

Exclusion Criteria:

  • Moderate or severe alcohol or cannabis use disorder in the last 3 months

    • Mild alcohol use disorder with abstinence of 30 days will be allowed
    • Mild marijuana use disorder will be allowed with abstinence for one week prior to participation
    • Any other DSM-5 drug use disorder in the last 3 months will be excluded
  • Lifetime bipolar disorder I or II, schizophrenia, schizoaffective disorder, obsessive-compulsive disorder, or major depressive disorder with psychotic features
  • Exposure to trauma in the last 3 months
  • Use of exclusionary antidepressant (trazodone, mirtazapine, doxepin, tricyclics), mood stabilizers (e.g., lithium), antipsychotic medication
  • Prominent suicidal or homicidal ideation or any suicidal behavior in the past 3 months on the Columbia Suicide Severity Rating Scale (C-SSRS) or increased risk of suicide that necessitates additional therapy or inpatient treatment
  • Pre-existing moderate sleep apnea or positive screen for sleep apnea by type III device (AHI>15) in the absence of adherence to effective treatment (such as CPAP or oral device)
  • Night shift work or extreme morning or evening tendencies in order to avoid the impact of circadian factors on subjective and objective sleep measures
  • Neurologic disorder or systemic illness affecting CNS function
  • Chronic or unstable medical illness, including:

    • unstable angina
    • myocardial infarction within the past 6 months
    • congestive heart failure
    • preexisting hypotension or orthostatic hypotension
    • heart block or arrhythmia
    • chronic renal or hepatic failure
    • pancreatitis
    • severe
  • History of severe traumatic brain injury as assessed by the Ohio State University Traumatic Brain Injury Identification Method (OSU-TBI ID)
  • Uncorrected hearing impairment
  • Mild cognitive impairment assessed by the (MOCA)
  • Pregnancy, breastfeeding and/or refusal to use effective (for women)
  • Previous adverse reaction to a hypnotic
  • Current use of benzodiazepines, strong inhibitors of , or Digoxin

    • The investigators will require that all participants do not consume heavy amounts of alcohol per week (>7 drinks for women, >14 drinks for men) or use illicit drugs for one week prior to participation
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40,120 participants (estimated)

Study arms

  • Experimental
    Suvorexant

    Suvorexant pills (10-20 milligrams)

    Drug: Suvorexant

  • Placebo comparator
    Placebo

    Matching placebo pills

    Drug: Placebo

Interventions

  • Suvorexant pills (10-20 milligrams)

  • DrugPlacebo

    Matching placebo pills

06

What researchers measure

Primary outcomes

  1. Enrollment

    Goal of enrolling 40 individuals to achieve a total of 30 completers by the end of month 23.

    Time frame: Month 4-23

  2. Medication Adherence

    Pill count and adherence to instructions over 7 study nights

    Time frame: Month 4-23

  3. Side effect reports

    Serious Adverse Events (SAEs)

    Time frame: Month 4-23

  4. Post-randomization drop out

    Post-randomization drop-out rates

    Time frame: Month 4-23

  5. Fear conditioning and extinction

    Fear conditioning (greater SC responses to CS+ cues vs CS- cues) and fear extinction (differential SC responses to CS+ and CS- cues that diminish over repeated trials) in the combined sample

    Time frame: Month 4-23

  6. Rates of technical malfunction

    Rates of technical malfunction (SC levels that are missing or \<.02 microsiemens) and or non-responding to the UCS (e.g., SCR\<.05 microsiemens)

    Time frame: Month 4-23

  7. Electrodermal Activity

    Differential SC responses to CS+ and CS- cues during extinction retention and 2) during reinstatement.

    Time frame: Years 2-7

Secondary outcomes

  1. Insomnia Severity Index

    Self-reported sleep

    Time frame: Years 2-7

  2. Sleep Electroencephalogram (EEG)

    Total sleep time, rapid eye movement (REM)

    Time frame: Years 2-7

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Mar 2032, 68 months after the start.

Of 53 non-industry phase 4 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 59. This study's planned 68 months is above that.

Counting every sponsor, half of 58 studies reached it within 28 months; a quarter within 17 and three quarters within 55.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Jan 23, 2025
StartActual
Jul 1, 2026was Jun 2026
Primary completionEst.
Mar 1, 2032
CompletionEst.
Jun 30, 2032
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
Show 2 sites
  • San Francisco VA Medical Center, San Francisco, CA · San Francisco, United Statesno status→Recruiting
  • Ralph H. Johnson VA Medical Center, Charleston, SC · Charleston, United Statesno status→Not yet recruiting
Nov 5, 2026
Start date
Jun 1, 2026→Jul 1, 2026 (actual)
Nov 5, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedenrollmentEnrollmentTime frame: Month 4-23
  • EditedsideSide effect reportsTime frame: Month 4-23
Nov 5, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedSleep Electroencephalogram (EEG)Time frame: Years 2-7
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
    Show 2 sites
    • San Francisco VA Medical Center, San Francisco, CA · San Francisco, United Statesno status→Recruiting
    • Ralph H. Johnson VA Medical Center, Charleston, SC · Charleston, United Statesno status→Not yet recruiting
    Start date Jun 1, 2026→Jul 1, 2026 (now actual)
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedenrollmentEnrollmentTime frame: Month 4-23
    • EditedsideSide effect reportsTime frame: Month 4-23
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedSleep Electroencephalogram (EEG)Time frame: Years 2-7
    + 3 other changes: identifiers, verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06788522
Responsible party
Sponsor
First posted
Jan 23, 2025
Start date
Jul 1, 2026
Primary completion
Mar 1, 2032 (estimated)
Completion
Jun 30, 2032 (estimated)
Last update
Nov 5, 2026

Study contacts

Sabra S Inslicht, PhD
Contact
sabra.inslicht@va.gov
(415) 221-4810 ext. 3341
Sabra S Inslicht, PhD
principal investigator · San Francisco VA Medical Center, San Francisco, CA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suvorexant

Start the discussion